Oncogene - Table of Contents alert Volume 34 Issue 19

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 34, Issue 19 (May 2015) In this issue Reviews Original Articles Corrigendum Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Featured contents published recently in Experimental & Molecular Medicine (EMM):  Special Feature on Neurodegenerative Diseases and their Therapeutic Approaches  Special Feature on Epstein-Barr Virus and Human Cancer EMM publishes the latest and most important advances in genetic, molecular and cellular studies of human physiology and diseases.  Register for your Electronic Table of Contents e-alerts today!    Reviews Top −7/7q− syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity H Honda, A Nagamachi and T Inaba Oncogene 2015 34: 2413-2425; advance online publication, July 7, 2014; 10.1038/onc.2014.196 Abstract | Full Text BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future M Spaargaren, M F M de Rooij, A P Kater and E Eldering Oncogene 2015 34: 2426-2436; advance online publication, June 23, 2014; 10.1038/onc.2014.181 Abstract | Full Text Original Articles Top Inhibition of BMP signaling suppresses metastasis in mammary cancer P Owens, M W Pickup, S V Novitskiy, J M Giltnane, A E Gorska, C R Hopkins, C C Hong and H L Moses Oncogene 2015 34: 2437-2449; advance online publication, July 7, 2014; 10.1038/onc.2014.189 Abstract | Full Text Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis X-D Liu, J Yao, D N Tripathi, Z Ding, Y Xu, M Sun, J Zhang, S Bai, P German, A Hoang, L Zhou, D Jonasch, X Zhang, C J Conti, E Efstathiou, N M Tannir, N T Eissa, G B Mills, C L Walker and E Jonasch Oncogene 2015 34: 2450-2460; advance online publication, July 7, 2014; 10.1038/onc.2014.199 Abstract | Full Text Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters S K Mungamuri, S Wang, J J Manfredi, W Gu and S A Aaronson Oncogene 2015 34: 2461-2470; advance online publication, July 14, 2014; 10.1038/onc.2014.198 Abstract | Full Text Loss of Cdh1 and Trp53 in the uterus induces chronic inflammation with modification of tumor microenvironment G R Stodden, M E Lindberg, M L King, M Paquet, J A MacLean, J L Mann, F J DeMayo, J P Lydon and K Hayashi Oncogene 2015 34: 2471-2482; advance online publication, July 7, 2014; 10.1038/onc.2014.193 Abstract | Full Text Polyoma small T antigen triggers cell death via mitotic catastrophe A T Pores Fernando, S Andrabi, O Cizmecioglu, C Zhu, D M Livingston, J M G Higgins, B S Schaffhausen and T M Roberts Oncogene 2015 34: 2483-2492; advance online publication, July 7, 2014; 10.1038/onc.2014.192 Abstract | Full Text Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist V Ubertini, G Norelli, D D'Arcangelo, A Gurtner, E Cesareo, S Baldari, M P Gentileschi, G Piaggio, P Nisticò, S Soddu, A Facchiano and G Bossi Oncogene 2015 34: 2493-2504; advance online publication, July 7, 2014; 10.1038/onc.2014.191 Abstract | Full Text FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction D-W Wu, M-C Lee, N-Y Hsu, T-C Wu, J-Y Wu, Y-C Wang, Y-W Cheng, C-Y Chen and H Lee Oncogene 2015 34: 2505-2515; advance online publication, July 7, 2014; 10.1038/onc.2014.184 Abstract | Full Text Physical and functional interaction of the TPL2 kinase with nucleophosmin D C Kanellis, S Bursac, P N Tsichlis, S Volarevic and A G Eliopoulos Oncogene 2015 34: 2516-2526; advance online publication, July 7, 2014; 10.1038/onc.2014.183 Abstract | Full Text The PI3K/Akt signal hyperactivates Eya1 via the SUMOylation pathway Y Sun, S Kaneko, X K Li and X Li Oncogene 2015 34: 2527-2537; advance online publication, June 23, 2014; 10.1038/onc.2014.179 Abstract | Full Text Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3 Z Shi, Z Li, Z J Li, K Cheng, Y Du, H Fu and F R Khuri Oncogene 2015 34: 2538-2545; advance online publication, June 30, 2014; 10.1038/onc.2014.171 Abstract | Full Text Corrigendum Top FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction D-W Wu, M-C Lee, N-Y Hsu, T-C Wu, J-Y Wu, Y-C Wang, Y-W Cheng, C-Y Chen and H Lee Oncogene 2015 34: 2546; 10.1038/onc.2014.465 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.